| Therapeutic | Sonelokimab1 |
| Target 1 | IL17A |
| Heavy Chain 1 | DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYVVGWFRQAPGKEREFIGAISGSGESIYYAVSEKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTADQEFGYLRFGRSEYWGQGTLVTVSS |
| Light Chain 1 | na |
| 100% seqID Fv 1 Structure | None |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | ALB |
| Heavy Chain 2 | EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS |
| Light Chain 2 | na |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
| Format | Trispecific Single Domains (VH-VH'-VH''); Bispecific Entry 1 |
| Isotype | na;na |
| Highest Clinical Trial (Aug '23) | Phase-II |
| Estimated Status (Aug '23) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2019 |
| INN Year Recommended | 2020 |
| Companies Involved | Ablynx, Avillion, MoonLake Immunotherapeutics, Merck Serono |
| Conditions Approved | na |
| Conditions Active | Hidradenitis suppurativa, Psoriasis, Psoriatic arthritis, Ankylosing spondylitis |
| Conditions Discontinued | na |
| Notes | VH-VH' portion. Joint entry with Sonelokimab2 (trispecific). Humanised: Llama/Human |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
